Overview

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

Status:
Terminated
Trial end date:
2021-08-02
Target enrollment:
Participant gender:
Summary
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Pliant Therapeutics, Inc.